A CRISPR therapy that edits genes inside the body, with no need to remove a patient's cells, is still working four years after treatment. It switches off a liver gene behind a rare disease that causes painful, dangerous swelling, and is poised to be the first of its kind to win FDA approval.
Current gene-editing treatments require removal of a participant’s cells, a complex and costly approach.